Fully Automated Blood-Based Assays Measure Biomarker for Neurodegenerative Diseases within 35 Minutes

Neurofilament light (NfL) is considered to be a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies in conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as in acute situations like traumatic brain injury (TBI). Now, researchers and clinical research professionals across the world can further study the clinical utility of this promising biomarker by using newly-launched biomarker tests that enable the quantitative measurement of NfL.

Fujirebio (Gent, Belgium) has expanded its assay menu in the field of neurodegenerative diseases by launching the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood CLEIA (chemiluminescent enzyme immunoassay) assays for the LUMIPULSE G immunoassay systems. The assays enable the quantitative measurement of NfL in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, in only 35 minutes. The assays are available for Research Use Only and will allow researchers and clinical research professionals to further examine the clinical utility of NfL in diverse disease conditions like multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as TBI.

Laboratory professionals can opt for their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardized immunoassay system family is widely available and used by routine labs which are active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform fulfills the required throughput, quality, and regulatory requirements for supporting potential future routine use of NfL apart from the existing portfolio.

“In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” said Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative disease field as quickly as possible.”

Related Links:
Fujirebio

Visit expo >

Unit-Dose Twist-Tip BFS

New

Platinum Supplier

Diagnostic Reader

Acucy System

New

Automated Chemistry Analyzer

TC-Matrix 600

New

Platinum Supplier

Ultra-Low PSA Control

Prostate-Specific Antigen Control